Christoph M. Dehnhardt

Structural basis of Nav1.7 inhibition by an isoform-selective small-molecule antagonist

Shivani Ahuja, Susmith Mukund, Lunbin Deng et al. · Science · 2015 · 327 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Bis(morpholino-1,3,5-triazine) Derivatives: Potent Adenosine 5′-Triphosphate Competitive Phosphatidylinositol-3-kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of Compound <b>26</b> (PKI-587), a Highly Efficacious Dual Inhibitor

Aranapakam M. Venkatesan, Christoph M. Dehnhardt, Efren Delos Santos et al. · Journal of Medicinal Chemistry · 2010 · 212 citations · Full text

Medicine, Oncology, Pharmacology +14

Antitumor Efficacy of PKI-587, a Highly Potent Dual PI3K/mTOR Kinase Inhibitor

Robert Mallon, Larry Feldberg, Judy Lucas et al. · Clinical Cancer Research · 2011 · 170 citations · Full text

Medicine, Oncology, Pharmacology +17

Discovery of Clinical Candidate 1-{[(2 <i>S</i> ,3 <i>S</i> ,4 <i>S</i> )-3-Ethyl-4-fluoro-5-oxopyrrolidin-2-yl]methoxy}-7-methoxyisoquinoline-6-carboxamide (PF-06650833), a Potent, Selective Inhibitor of Interleukin-1 Receptor Associated Kinase 4 (IRAK4), by Fragment-Based Drug Design

Katherine L. Lee, Catherine M. Ambler, David R. Anderson et al. · Journal of Medicinal Chemistry · 2017 · 145 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +17

Lead Optimization of N-3-Substituted 7-Morpholinotriazolopyrimidines as Dual Phosphoinositide 3-Kinase/Mammalian Target of Rapamycin Inhibitors: Discovery of PKI-402

Christoph M. Dehnhardt, Aranapakam M. Venkatesan, Efren Delos Santos et al. · Journal of Medicinal Chemistry · 2009 · 78 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +16